Home
NewsNewsCSG.BIO has gone ahead with the acquisition of Hanabusa IVF, Asian Egg Bank, thereby making it a world leader in reproductive medicine and cutting-edge clinics with enhanced patient reach and advanced laboratory capabilities.
On March 5, 2026, CSG.BIO, which is a global life sciences and healthcare platform with services across fertility, reproductive health, and biologic preservation, as well as family-building, went ahead with the acquisition of Hanabusa IVF, Asian Egg Bank.
Hanabusa IVF, which is based in San Diego, California, is known for its customised fertility care, which includes its unique approach when it comes to mini-IVF along with lower-stimulation treatments. Asian Egg Bank is now one of the leading options for intended parents and fertility clinics to find Asian donor eggs. The two groups together give CSG.BIO a strong platform for reproductive care and donor eggs that is becoming more important in the US and around the world.
The acquisition of Hanabusa IVF, Asian Egg Bank, adds to the present speciality IVF practice of CSG.BIO, the New England Fertility Institute in Stamford, Connecticut. It turns CSG.BIO into a world leader when it comes to reproductive medicine, with cutting-edge clinics located near major domestic as well as international gateways on both coasts. This next phase helps Hanabusa IVF and New England Fertility Institute work together toward a bigger long-term goal – making personalised fertility care more available, establishing internationally connected surrogacy along with third-party reproduction services, and continuing to expand their specialised mini-IVF offering within the large global network of CSG.BIO.
It is well to be noted that the strategic fit is just as crucial to the Asian Egg Bank. Other organisations in the group include CryoChoice and AlphaCord, as well as CellSave. This kind of sync creates real synergy between family-building support and biologic storage along with reproductive services, and it also makes the infrastructure much stronger when it comes to future growth.
“Joining CSG.BIO gives us the opportunity to build on what makes Hanabusa IVF and Asian Egg Bank so distinctive while gaining the strength of a broader global platform,” said Peter Fuzesi, CEO of Hanabusa IVF and Asian Egg Bank. “We see strong alignment between our mission and CSG.BIO’s capabilities across fertility, preservation, and family-building services. This next step allows us to continue advancing personalised care in San Diego while expanding what we can offer patients, intended parents, and partners around the world.”
“We are thrilled to welcome Hanabusa IVF and Asian Egg Bank into the CSG.BIO family,” said Sarah Al-Hajali, CEO of CSG.BIO. “Hanabusa IVF has built an exceptional reputation for thoughtful, patient-centred fertility care, and Asian Egg Bank adds an important and highly specialised donor egg platform to our growing organisation. Together, these additions strengthen our vision for the future of reproductive medicine, family building, and biologic preservation, and we are excited for what lies ahead.”
Provident Healthcare Partners gave Hanabusa IVF and Asian Egg Bank advice on the transaction by helping it go through. Corbel Capital Partners, an independent investment firm that is based in Los Angeles that executes customised structured debt or equity investments in lower-market businesses and works with management to create value, provided the financing for the deal.
Abu Dhabi University and FertiClinic Group have joined forces to establish the FertiClinic Reproductive Research Lab, an advanced reproductive research lab in Abu Dhabi housing IVF, andrology, and cryopreservation facilities. The partnership supports UAE national priorities, bridges academic and clinical expertise, and advances fertility innovation across the region.
NHS Kent and Medway has overhauled its fertility funding policy in a move that sees NHS cuts IVF access for thousands of patients. Effective 1 April 2026, the eligible age ceiling drops from 40 to 38, funded cycles fall from two to one, and embryo transfers are capped at two.
ASEAN's First Telemedicine IVF by Inspire IVF introduces a new era of remote fertility care. Combining AI technology with expert consultation, the platform enables global access, real-time monitoring, and personalised treatment planning, positioning Thailand as a leading hub for fertility services and advancing digital transformation in reproductive healthcare.
Wisconsin lawmakers from both parties are proposing bills to reduce IVF treatment costs. Republicans suggest a $5,000 tax credit for expenses, while Democrats want mandatory insurance coverage. With IVF cycles costing $20,000-$30,000 and 170,000 residents facing infertility, both parties seek affordable solutions through different approaches.
The AI-specialized Infertility Center, which is the largest in Asia, is open in Magok, Seoul and has begun its full-scale medical services from November 17 thereby marking the new era when it comes to fertility in the region.
Alife Health secured CE Mark approval for its AI-powered embryo selection tool, Embryo Predict, under EU MDR, expanding its fertility technology presence across Europe.
